RxSight Q1 revenue up 157% to $8.9M; raises 2022 revenue guidance

RxSight, Inc.

2023-Q1 EPS reported -$0.64 revenue$8,942,000

Revenue $8.9M (+157% YoY); LDD sales 40 units (+208%), installed base 246 (+134%).
Net loss $17.6M ($0.64/share); adjusted net loss $14.9M ($0.54/share).
2022 revenue guidance raised to $41.5-45.5M from $40-44M, implying 84-101% annual growth.
Amended Oxford Finance loan: extends draw periods for remaining $20M, interest-only period to 2025.
Procedure volumes: 4,166 LALs sold (+166% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.